Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Azithromycin
Treatment for Pertussis
Typical Dosage: Infants <6 months: 10 mg/kg/day; Older: 500 mg Day 1, then 250 mg daily
Effectiveness
88%
Safety Score
70%
Clinical Trials
4
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Infants <6 months: 10 mg/kg/day; Older: 500 mg Day 1, then 250 mg daily
Time to Effect
1-2 days (bacterial eradication)
Treatment Duration
5 days
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20
Monitoring:$600
Side Effect Mgmt:$5
Total Annual:$625
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$31.25
Cost per Remission
$33.33
Prescription Access Economics
Annual Societal Loss per Patient
$-2,795
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$30/year
Travel + wait time
Insurance Admin Cost
$15/year
Prior auth, claims
Rx Price
$20/year
Potential OTC Price
$10/year
Estimated if OTC available
Early Treatment Benefit
+0.02 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWAzithromycin Outcomes
for Pertussis
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+80%
Remission Rate
+75%
Common Side Effects
Diarrhea
+8%
Nausea
+6%
Abdominal pain
+4%
QT prolongation
+0.1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Azithromycin in Pertussis
Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks
NCT05847322RECRUITINGNA
72 participants
INTERVENTIONAL
Southampton, United Kingdom
Started: Dec 6, 2022
Completed Clinical Trials
2 completed trials for Azithromycin in Pertussis
Pertussis Challenge Study in Adults Vaccinated With BPZE1
NCT05461131COMPLETEDPHASE2
53 participants
INTERVENTIONAL
Oxford, United Kingdom +1 more
Started: Jun 20, 2022
Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure
NCT00469274COMPLETEDNA
1.1K participants
INTERVENTIONAL
Nashville, United States
Started: May 1, 2007